Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)

Brian Ball, Shukaib Arslan, Paul Koller, Dat Ngo, Michelle Afkhami, Amandeep Salhotra, Monzr M. Al Malki, Ahmed Aribi, Haris Ali, Karamjeet Sandhu, Salman Otoukesh, Idoroenyi Amanam, Hoda Pourhassan, Andrew Artz, Peter Curtin, Anthony S. Stein, Ryotaro Nakamura, Guido Marcucci, Eileen Smith, Vinod Pullarkat, Ibrahim Aldoss